Bumcrot
David Bumcrot, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20100240881 | THERAPEUTIC COMPOSITIONS - This application relates to therapeutic siRNA agents and methods of making and using the agents. | 09-23-2010 |
20130144048 | THERAPEUTIC COMPOSITIONS - This application relates to therapeutic siRNA agents and methods of making and using the agents. | 06-06-2013 |
20140235693 | SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT - The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpinal gene, and methods of using such dsRNA compositions to inhibit expression of Serpinal. In one embodiment, an iRNA for inhibiting expression of a Serpinal gene includes at least two sequences that are complementary to each other. The iRNA includes a sense strand having a first sequence and an antisense strand having a second sequence. The antisense strand includes a nucleotide sequence that is substantially complementary to at least part of an mRNA encoding Serpinal, and the region of complementarity is 30 nucleotides or less, and at least 15 nucleotides in length. Generally, the iRNA is 19 to 24, e.g., 19 to 21 nucleotides in length. | 08-21-2014 |
20140309411 | THERAPEUTIC COMPOSITIONS - This application relates to therapeutic siRNA agents and methods of making and using the agents. | 10-16-2014 |
David A. Bumcrot, Belmont, MA US
Patent application number | Description | Published |
---|---|---|
20150252358 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) - CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed. | 09-10-2015 |
David Anton Bumcrot, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20150291954 | ORGANIC COMPOSITIONS TO TREAT BETA-CATENIN-RELATED DISEASES - The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin. | 10-15-2015 |